Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

Phase 3 Completed 483 enrolled Endo USA Inc., a Keenova Therapeutics Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835 (Collagenase Clostridium Histolyticum \[CCH\]-aaes) lasts in the treatment of Cellulite.

Timeline

Start: 2018-04-26
Primary completion: 2021-10-08
Completion: 2021-10-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Collagenase Clostridium Histolyticum	Protein / enzyme biologic	1.68 mg	—

Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)

Summary

Timeline

Drugs

Indications